|Table of Contents|

Prognostic value of circulating tumor cells in IRE combined with microsphere embolization for hepatocellular carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 04
Page:
619-622
Research Field:
Publishing date:

Info

Title:
Prognostic value of circulating tumor cells in IRE combined with microsphere embolization for hepatocellular carcinoma
Author(s):
Zeng Jianying; Zhou Xulong; Yang Huifei; Chen Jibing; Niu Lizhi
Department of Pathology,Fuda Cancer Hospital，Jinan University，Guangdong Guangzhou 510665，China.
Keywords:
hepatocellular carcinoma; circulating tumor cells; irreversible electroporation
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2019.04.019
Abstract:
Objective:To evaluate the diagnostic value and clinical significance of CanPatroTM CTC-enrichment and in situ hybridization (ISH) in the treatment of irreversible electroporation (IRE) combined with transarterial chemoembolization with drug-eluting beads (DEB-TACE) in the treatment of hepatocellular carcinoma (HCC).Methods:The peripheral blood samples of patients with hepatocellular carcinoma who received IRE combined DEB-TACE,IRE monotherapy and DEB-TACE monotherapy in our hospital from August 2015 to March 2018 were detected by CTCs.The peripheral blood of 10 healthy persons was collected as control.The changes of CTCs in HCC patients were observed before and after treatment.Results:Total of 82 cases of CTCs were detected in peripheral blood of 91 patients with HCC 7 days before operation.The median blood CTCs per 5 ml was 8.5 (6,13),and there was no CTCs in the peripheral blood of 10 healthy persons.There was a positive correlation between the preoperative tumor marker AFP level and the number of CTCs in peripheral blood of the patients (P＜0.000 1).There was no significant difference in CTCs between the three groups before treatment (P＞0.05).One month after treatment,there were significant differences in CTCs before and after treatment in each group (P＜0.05).In both group IRE+DEB-TACE and group IRE,the postoperative CTCs were significantly lower than that in DEB-TACE group (P＜0.05).Conclusion:CanPatroTM CTC-enrichment and ISH can detect CTCs of patients with HCC effectively.Compared to DEB-TACE,IRE or combined DEB-TACE for the treatment of HCC may help to improve short-term efficacy.

References:

［1］Bruix J,Reig M,Sherman M.Evidence-based diagnosis,staging,and treatment of patients with hepatocellular carcinoma［J］.Gastroenterology,2016,150(4):835-853.
［2］Siegel RL,Miller KD,Jemal A.Cancer statistics,2018［J］.CA Cancer J Clin,2018,68(1):7-30.
［3］Cohen EI,Field D,Lynskey GE,et al.Technology of irreversible electroporation and review of its clinical data on liver cancers ［J］.Expert Rev Med Devices,2018,15(2):99-106.
［4］Sutter O,Calvo J,N'Kontchou G,et al.Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques:A retrospective single-center case series ［J］.Radiology,2017,284(3):877-886.
［5］Niessen C,Beyer LP,Pregler B,et al.Percutaneous ablation of hepatic tumors using irreversible electroporation:A prospective safety and midterm efficacy study in 34 patients ［J］.J Vasc Interv Radiol,2016,27(4):480-486.
［6］Niu LZ,Liu GF,Zeng JY,et al.Safety and short-term effect of irreversible electroporation ablation of hepatic neoplasms ［J］.Chinese J Radiol,2016,50(7):526-530.［牛立志,刘桂凤,曾健滢,等.肝恶性肿瘤不可逆电穿孔消融的安全性和近期疗效 ［J］.中华放射学杂志,2016,50(7):526-530.］
［7］Vogel JA,Rombouts SJ,de Rooij T,et al.Induction chemotherapy followed by resection or irreversible electroporation in locally advanced pancreatic cancer (IMPALA):A prospective cohort study ［J］.Ann Surg Oncol,2017,24(9):2734-2743.
［8］Mansson C,Brahmstaedt R,Nilsson A,et al.Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy ［J］.Eur J Surg Oncol,2016,42(9):1401-1406.
［9］Langan RC,Goldman DA,D'Angelica MI,et al.Recurrence patterns following irreversible electroporation for hepatic malignancies ［J］.J Surg Oncol,2017,115(6):704-710.
［10］Wang YX,De Baere T,Idee JM,et al.Transcatheter embolization therapy in liver cancer:an update of clinical evidences ［J］.Chin J Cancer Res,2015,27(2):96-121.
［11］Zurstrassen CE,Gireli LPO,Tyng CJ,et al.Safety and efficacy of HepaSphere 50-100 mum in the treatment of hepatocellular carcinoma ［J］.Minim Invasive Ther Allied Technol,2017,26(4):212-219.
［12］Liu HY,Qian HH,Zhang XF,et al.Improved method increases sensitivity for circulating hepatocellular carcinoma cells［J］.World J Gastroenterol,2015,21(10):2918-2925.
［13］Kaifi JT,Kunkel M,Dicker DT,et al.Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver ［J］.Cancer Biol Ther,2015,16(5):690-698.
［14］Onstenk W,Kraan J,Mostert B,et al.Improved circulating tumor cell detection by a combined EpCAM and MCAM cell search enrichment approach in patients with breast cancer undergoing neoadjuvant chemotherapy ［J］.Mol Cancer Ther,2015,14(3):821-827.
［15］Shi J,Li Y,Liang S,et al.Circulating tumour cells as biomarkers for evaluating cryosurgery on unresectable hepatocellular carcinoma ［J］.Oncol Rep,2016,36(4):1845-1851.
［16］Lin M,Liang SZ,Shi J,et al.Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer ［J］.Immunol Lett,2017,191:10-15.
［17］Wang S,Zheng Y,Liu J,et al.Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation ［J］.J Investig Med,2018,66(5):1-6.
［18］Zhu Ling,Xiang Min,Liu Xin,et al.Advances in research on circulating tumor cells［J］.Modern Oncology,2014,22(11):2746-2748.［朱玲，向敏，刘馨,等.循环肿瘤细胞临床应用的新进展［J］.现代肿瘤医学,2014,22(11):2746-2748.］

Memo

Memo:
广州市天河区科技计划项目（编号：201504KW010）
Last Update: 1900-01-01